Skip to main navigation
Skip to content
Contact Us
Millendo
  • Our Story
  • Our Patients
    • Clinical Research Overview
    • Livoletide Pivotal Study
    • Nevanimibe Clinical Study
    • Educational Resources and Advocacy
    • Expanded Access
  • Our Science
    • Pipeline
    • Disease Areas
    • Livoletide
    • Nevanimibe
    • MLE-301
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports & SEC Filings
    • Investor Resources
  • Join Our Team
Contact Us
Millendo
  • Our Story
  • Our Patients
    • Clinical Research Overview
    • Livoletide Pivotal Study
    • Nevanimibe Clinical Study
    • Educational Resources and Advocacy
    • Expanded Access
  • Our Science
    • Pipeline
    • Disease Areas
    • Livoletide
    • Nevanimibe
    • MLE-301
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports & SEC Filings
    • Investor Resources
  • Join Our Team
Stock Quote & Chart
  • Stock Quote & Chart
  • Historical Price Lookup

Stock Quote & Chart

Price Change
Volume % Change  
Intraday High 52 Week High
Intraday Low 52 Week Low
Today's Open Currency US Dollar
Previous Close Exchange


Copyright West LLC. Minimum 15 minutes delayed.

Shareholder Tools

Print Page Email Page RSS Feeds Email Alerts Financial Tear Sheet

US Offices

Corporate Headquarters

110 Miller Avenue, Suite 100
Ann Arbor, MI 48104
734-845-9000
millendo@millendo.com

Lexington Office

420 Bedford Street,
Suite 260
Lexington, MA 02420

Europe Office

 
Lyon Office

Millendo Therapeutics SAS
15 Chemin du Saquin
Espace Européen,
Building G
69130 Ecully
France
Tel +33 472 18 94 28
Fax +33 478 33 36 29

  • Our Story
  • Our Patients
  • Our Science
  • Investors & Media
  • Join Our Team
  • Privacy Policy
Copyright © 2019 Millendo Therapeutics, Inc. All rights reserved.
Scroll to Top